< -5%

-5% to -3%

-3% to 0%

GE Power India

0% to 3%

3% to 5%

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticalsdrugs/zyduslifesciences/CHC">Zydus Lifesciences</a> share price down marginally in the opening trade on November 6 following the company received zero observation from USFDA.

At 09:22 hrs Zydus Lifesciences was quoting at Rs 971.00, down Rs 1.85, or 0.19 percent, on the BSE.

The United States Food and Drug Administration (USFDA) has conducted an inspection at the group’s manufacturing plant located SEZ – II, Ahmedabad, between August 11-14, 2025.

The inspection was a pre-approval inspection (PAI) and concluded with NIL observations.

The Establishment Inspection Report (EIR) has classified the facility as No Action Indicated (NAI).

<a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-firm-start-us-asian-markets-gain-liveblog-13655439.html">Catch all the market action on our live blog</a>

On November 4, the company received tentative approval from the USFDA for Budesonide delayed-release capsules, 4 mg, which is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and older.

Budesonide capsules will be produced at is Zydus Pharmaceuticals Ltd, SEZ-II.

In October, the company received the Establishment Inspection Report (EIR) from the USFDA for an inspection conducted at its manufacturing facility located at Baddi, from August 4-13, 2025.

In the previous trading session, the share closed at Rs 972.85, down Rs 7.90, or 0.81 percent.

The share touched a 52-week high of Rs 1,059.00 and a 52-week low of Rs 797.05 on 19 September, 2025 and 07 April, 2025, respectively.

Currently, the stock is trading 8.31 percent below its 52-week high and 21.82 percent above its 52-week low.

The market capitalisation of the company stands at Rs 97,705.32 crore.

Ownership, Material Conflicts of Interest and Disciplinary History

MCD is a wholly owned subsidiary of Network 18 Media & Investments Ltd ("Network18"), in which Independent Media Trust (IMT) holds 56.89% stake. Reliance Industries Limited ("RIL") is the sole beneficiary of IMT. Network18 and RIL and their subsidiaries, joint ventures and associates can be considered as associates of MCD.

Details of Associate

Receipt of Compensation

Third-Party Compensation

Employment History

Market-Making Activities

Use of Artificial Intelligence

Zydus Lifesciences gets EIR from USFDA for Ahmedabad facility; shares trade lower

Zydus Lifesciences share price down marginally in the opening trade on November 6 following the company received zero observation from USFDA.

At 09:22 hrs Zydus Lifesciences was quoting at Rs 971.00, down Rs 1.85, or 0.19 percent, on the BSE.

The United States Food and Drug Administration (USFDA) has conducted an inspection at the group’s manufacturing plant located SEZ – II, Ahmedabad, between August 11-14, 2025.

The inspection was a pre-approval inspection (PAI) and concluded with NIL observations.

The Establishment Inspection Report (EIR) has classified the facility as No Action Indicated (NAI).

Catch all the market action on our live blog

On November 4, the company received tentative approval from the USFDA for Budesonide delayed-release capsules, 4 mg, which is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and older.

Budesonide capsules will be produced at is Zydus Pharmaceuticals Ltd, SEZ-II.

In October, the company received the Establishment Inspection Report (EIR) from the USFDA for an inspection conducted at its manufacturing facility located at Baddi, from August 4-13, 2025.

In the previous trading session, the share closed at Rs 972.85, down Rs 7.90, or 0.81 percent.

The share touched a 52-week high of Rs 1,059.00 and a 52-week low of Rs 797.05 on 19 September, 2025 and 07 April, 2025, respectively.

Currently, the stock is trading 8.31 percent below its 52-week high and 21.82 percent above its 52-week low.

The market capitalisation of the company stands at Rs 97,705.32 crore.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/marksanspharma/MP21">Marksans Pharma</a> share price rose in the opening trade on November 6 following the company received cancer drug approval from UK MHRA.

At 09:20am, Marksans Pharma was quoting at Rs 189.10, up Rs 2.35, or 1.26 percent, on the BSE.

The company's wholly owned subsidiary Relonchem in UK has received marketing authorization for its product Exemestane 25mg film-coated tablets from UK MHRA.

<a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-firm-start-us-asian-markets-gain-liveblog-13655439.html">Catch all the market action on our live blog</a>

A meeting of the board of directors of the company will be held on November 13, 2025, to consider and approve the unaudited financial results of the company (both standalone and consolidated) for the quarter and half year ended September 30, 2025.

In October Relonchem received marketing authorization for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets, from UK MHRA.

In the previous trading session, the share closed at Rs 186.75, down Rs 3.70, or 1.94 percent.

The share touched a 52-week high of Rs 358.50 and a 52-week low of Rs 162.05 on 05 December, 2024 and 07 October, 2025, respectively.

Currently, the stock is trading 47.25 percent below its 52-week high and 16.69 percent above its 52-week low.

The market capitalisation of the company stands at Rs 8,569.33 crore.

Marksans Pharma shares rise on breast cancer drug approval from UK MHRA

Marksans Pharma share price rose in the opening trade on November 6 following the company received cancer drug approval from UK MHRA.

At 09:20am, Marksans Pharma was quoting at Rs 189.10, up Rs 2.35, or 1.26 percent, on the BSE.

The company's wholly owned subsidiary Relonchem in UK has received marketing authorization for its product Exemestane 25mg film-coated tablets from UK MHRA.

Catch all the market action on our live blog

A meeting of the board of directors of the company will be held on November 13, 2025, to consider and approve the unaudited financial results of the company (both standalone and consolidated) for the quarter and half year ended September 30, 2025.

In October Relonchem received marketing authorization for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets, from UK MHRA.

In the previous trading session, the share closed at Rs 186.75, down Rs 3.70, or 1.94 percent.

The share touched a 52-week high of Rs 358.50 and a 52-week low of Rs 162.05 on 05 December, 2024 and 07 October, 2025, respectively.

Currently, the stock is trading 47.25 percent below its 52-week high and 16.69 percent above its 52-week low.

The market capitalisation of the company stands at Rs 8,569.33 crore.

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and appointments, here’s a quick look at which stocks will be in focus in today's trade:

<a href="https://www.moneycontrol.com/markets/earnings/" target="_blank">Results Today</a>

Apollo Hospitals Enterprise, Lupin, Life Insurance Corporation of India, ABB India, Ola Electric Mobility, UPL, Zydus Lifesciences, Abbott India, Amber Enterprises India, Amara Raja Energy &amp; Mobility, Aster DM Healthcare, Cholamandalam Investment and Finance Company, Crompton Greaves Consumer Electricals, Cummins India, Godrej Properties, Hexaware Technologies, Mankind Pharma, Multi Commodity Exchange of India, Saatvik Green Energy, and Smartworks Coworking Spaces will announce their quarterly earnings on November 6.

<a href="https://www.moneycontrol.com/markets/earnings/" target="_blank">Quarterly Earnings</a>

<a href="https://www.moneycontrol.com/india/stockpricequote/diversified/grasimindustries/GI01">Grasim Industries</a> Q2 (Standalone YoY)

Profit jumps 11.6% to Rs 804.6 crore Vs Rs 720.9 crore

Revenue soars 26% to Rs 9,610.3 crore Vs Rs 7,623.3 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/online-services/one97communicationspaytm/OC03">One 97 Communications Paytm</a> Q2 (Consolidated YoY)

Profit falls sharply to Rs 21 crore Vs Rs 928 crore

Revenue grows 24.2% to Rs 2,061 crore Vs Rs 1,659 crore

Exceptional loss at Rs 190 crore Vs exceptional gain of Rs 1,345 crore

Paytm partners with Groq to power real-time AI for payments and platform intelligence

<a href="https://www.moneycontrol.com/india/stockpricequote/transportlogistics/interglobeaviation/IA04">InterGlobe Aviation</a> Q2 (Consolidated)

Loss widens to Rs 2,582.1 crore Vs loss of Rs 986.7 crore

Revenue grows 9.3% to Rs 18,555.3 crore Vs Rs 16,969.6 crore

EBITDAR plunges 54.2% to Rs 1,114.3 crore Vs Rs 2,434 crore

EBITDAR margin drops to 6% Vs 14.3%

EBITDAR (excluding forex) zooms 42.5% to Rs 3,800.3 crore Vs Rs 2,666.8 crore

EBITDAR margin (excluding forex) expands to 20.5% Vs 15.7%

<a href="https://www.moneycontrol.com/india/stockpricequote/food-processing/britanniaindustries/BI">Britannia Industries</a> Q2 (Consolidated YoY)

Profit zooms 23.1% to Rs 654.5 crore Vs Rs 531.5 crore

Revenue grows 3.7% to Rs 4,840.6 crore Vs Rs 4,667.6 crore

Board appoints Rakshit Hargave as an Additional Whole-Time Director and Chief Executive Officer of Britannia

<a href="https://www.moneycontrol.com/india/stockpricequote/hotels/indianhotelscompany/IHC">Indian Hotels Company</a> Q2 (Consolidated YoY)

Profit sinks 48.6% to Rs 284.9 crore Vs Rs 554.6 crore

Revenue rises 11.8% to Rs 2,040.9 crore Vs Rs 1,826.1 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/courier-services/delhivery/D06">Delhivery</a> Q2 (Consolidated YoY)

Loss stands at Rs 50.4 crore Vs profit of Rs 10.2 crore

Revenue increases 16.9% to Rs 2,559.3 crore Vs Rs 2,189.7 crore

Vivek Pabari to take over as Chief Financial Officer of the company

<a href="https://www.moneycontrol.com/india/stockpricequote/computers-hardware/redington/RI37">Redington</a> Q2 (Consolidated YoY)

Profit jumps 23.8% to Rs 350.2 crore Vs Rs 282.9 crore

Revenue soars 16.8% to Rs 29,075.6 crore Vs Rs 24,895.6 crore.

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/godrejagrovet/GA03">Godrej Agrovet</a> Q2 (Consolidated YoY)

Profit falls 12% to Rs 84.3 crore Vs Rs 95.8 crore

Revenue increases 4.8% to Rs 2,567.4 crore Vs Rs 2,448.8 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/diamondjewellery/internationalgemmologicalinstituteindia/IGIIL">International Gemmological Institute India</a> Q2 (Consolidated YoY)

Profit grows 18.4% to Rs 129.8 crore Vs Rs 109.6 crore

Revenue jumps 21.4% to Rs 303.7 crore Vs Rs 250.1 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/banks-private-sector/csbbank/CB05">CSB Bank</a> Q2 (YoY)

Profit increases 15.8% to Rs 160.3 crore Vs Rs 138.4 crore

Net interest income soars 15.3% to Rs 423.6 crore Vs Rs 367.5 crore

Provisions &amp; contingencies zoom 357.6% to Rs 63.7 crore Vs Rs 13.9 crore

Gross NPA falls to 1.81% Vs 1.84% (QoQ)

Net NPA declines to 0.52% Vs 0.66% (QoQ)

<a href="https://www.moneycontrol.com/india/stockpricequote/electronics-components/kaynestechnologyindia/KTI">Kaynes Technology India</a> Q2 (Consolidated YoY)

Profit spikes 101.7% to Rs 121.4 crore Vs Rs 60.2 crore

Revenue zooms 58.4% to Rs 906.2 crore Vs Rs 572.1 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/hotels/chalethotels/CH03">Chalet Hotels</a> Q2 (Consolidated YoY)

Profit stands at Rs 154.8 crore Vs loss of Rs 138.5 crore

Revenue surges 95% to Rs 735.3 crore Vs Rs 377 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/paintsvarnishes/bergerpaintsindia/BPI02">Berger Paints India</a> Q2 (Consolidated YoY)

Profit falls 23.5% to Rs 206.4 crore Vs Rs 270 crore

Revenue rises 1.9% to Rs 2,827.5 crore Vs Rs 2,774.6 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/teamleaseservices/TS13">TeamLease Services</a> Q2 (Consolidated YoY)

Profit grows 12% to Rs 27.5 crore Vs Rs 24.6 crore

Revenue increases 8.4% to Rs 3,032 crore Vs Rs 2,796.8 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/fertilisers/deepakfertiliserspetrochemicalscorporation/DFP">Deepak Fertilisers &amp; Petrochemicals Corporation</a> Q2 (Consolidated YoY)

Profit rises 1.5% to Rs 213.2 crore Vs Rs 210.1 crore

Revenue soars 9.4% to Rs 3,005.8 crore Vs Rs 2,746.7 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/auto-ancillaries/mothersonsumiwiringindia/MSW">Motherson Sumi Wiring India</a> Q2 (Consolidated YoY)

Profit jumps 8.7% to Rs 165.3 crore Vs Rs 152 crore

Revenue surges 18.8% to Rs 2,761.9 crore Vs Rs 2,325.6 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/aerospacedefence/apollomicrosystems/AMS">Apollo Micro Systems</a> Q2 (Consolidated YoY)

Profit zooms 98.1% to Rs 31.1 crore Vs Rs 15.7 crore

Revenue surges 40.2% to Rs 225.3 crore Vs Rs 160.7 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/hospitalsmedical-services/metropolishealthcare/MH06">Metropolis Healthcare</a> Q2 (Consolidated YoY)

Profit grows 13.2% to Rs 52.7 crore Vs Rs 46.5 crore

Revenue increases 22.7% to Rs 429.2 crore Vs Rs 349.8 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/retail/adityabirlafashionretail/PFR">Aditya Birla Fashion and Retail</a> Q2 (Standalone YoY)

Loss narrows to Rs 90.9 crore Vs loss of Rs 138.7 crore

Revenue soars 7.5% to Rs 1,491.8 crore Vs Rs 1,387.4 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/shipping/gujaratpipavavport/GPP03">Gujarat Pipavav Port</a> Q2 (Consolidated YoY)

Profit zooms 112.9% to Rs 160.7 crore Vs Rs 75.5 crore

Revenue grows 31.8% to Rs 299.4 crore Vs Rs 227 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/engineering-heavy/gardenreachshipbuildersengineers/GRS01">Garden Reach Shipbuilders &amp; Engineers</a> Q2 (Consolidated YoY)

Profit spikes 57.3% to Rs 153.8 crore Vs Rs 97.8 crore

Revenue surges 45.5% to Rs 1,677.4 crore Vs Rs 1,152.9 crore

Stocks to Watch

<a href="https://www.moneycontrol.com/india/stockpricequote/banks-private-sector/rblbank/RB03">RBL Bank</a>

<a href="https://www.moneycontrol.com/india/stockpricequote/auto-carsjeeps/mahindramahindra/MM">Mahindra and Mahindra</a> is likely to sell its entire 3.45% stake in the bank, with the block size likely at $78 million (Rs 682 crore) and a floor price of Rs 317 per share, reports CNBC-TV18 quoting sources.

<a href="https://www.moneycontrol.com/india/stockpricequote/computers-software/tataconsultancyservices/TCS">Tata Consultancy Services</a>

The IT services, consulting, and business solutions company has expanded its 18-year partnership with ABB to modernize ABB’s global hosting operations, simplify its IT landscape, and strengthen its digital foundation to drive resilience and innovation.

<a href="https://www.moneycontrol.com/india/stockpricequote/power-transmissionequipment/adanienergysolutions/AT22">Adani Energy Solutions</a>

The company has signed an agreement with RSWM for the supply of 60 MW of renewable energy to RSWM’s multiple plant locations. RSWM invested Rs 60 crore under the Group Captive Scheme with a renewable generation company (genco) for the supply of 31.53 crore units of green power per annum to its manufacturing facilities across Rajasthan. With this addition, the contribution of renewable energy in RSWM’s total energy requirement will rise from the current 33% to 70% in the near future (two-thirds of its total energy mix).

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticalsdrugs/zyduslifesciences/CHC">Zydus Lifesciences</a>

The company has received an Establishment Inspection Report (EIR) from the USFDA (US Food and Drug Administration) for its manufacturing facility in SEZ II, Ahmedabad.

The USFDA conducted an inspection at the group’s manufacturing plant during August 11-14, 2025. The inspection was a Pre-Approval Inspection (PAI). The USFDA has concluded this inspection as closed, with no observations. The EIR has classified the facility as No Action Indicated (NAI).

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/marksanspharma/MP21">Marksans Pharma</a>

The company's wholly owned subsidiary, Relonchem in the UK, has received marketing authorization for its product Exemestane 25mg film-coated tablets from the UK MHRA. Exemestane tablets are used to treat hormone-positive breast cancer in postmenopausal women.

<a href="https://www.moneycontrol.com/india/stockpricequote/auto-lcvshcvs/forcemotors/FM01">Force Motors</a>

The company reported total sales of 2,835 units in the month of October, growing 32.1% compared to 2,146 units sold in the same month last year.

<a href="https://www.moneycontrol.com/india/stockpricequote/fertilizers/gujaratnarmadavalleyfertchem/GNV">Gujarat Narmada Valley Fertilizers and Chemicals Company</a>

The Board has approved the appointment of Manoj Kumar Das, IAS, as Director and Chairman of the company.

Bulk Deals

<a href="https://www.moneycontrol.com/india/stockpricequote/chemicals/stallionindiafluorochemicals/SIFL">Stallion India Fluorochemicals</a>

Promoter Shazad Sheriar Rustomji sold 8.08 lakh shares (equivalent to 1.01% of paid-up equity) in Stallion India at Rs 247.65 per share, valued at Rs 20.01 crore. The total promoters' shareholding in the company was 67.9 percent as of September 2025.

However, Savita Jayesh Shah acquired 4.04 lakh shares (0.5% stake), and Jayeshbhai Nagindas Shah bought 4.04 lakh shares (0.5% stake) in Stallion India at Rs 247.65 per share.

<a href="https://www.moneycontrol.com/india/stockpricequote/software/aaatechnologies/ATL">AAA Technologies</a>

Promoter Anjay Ratanlal Agarwal sold 1 lakh shares in the information technology and cyber security auditing and consulting company at Rs 93.1 per share for a total of Rs 93.1 lakh to Nautilus.

Mainboard Listing

Orkla India

SME Listing

Safecure Services

Stocks Trade Ex-Dividend

Hindustan Petroleum Corporation
Nippon Life India Asset Management
Share India Securities
TD Power Systems
Vaibhav Global

Stocks to Watch Today: RBL Bank, TCS, Zydus Life, Britannia, Gujarat Pipavav, Garden Reach, Apollo Micro Systems, Chalet Hotels, CSB Bank, Orkla India, Paytm in focus on 06 November

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and appointments, here’s a quick look at which stocks will be in focus in today's trade:

Results Today

Apollo Hospitals Enterprise, Lupin, Life Insurance Corporation of India, ABB India, Ola Electric Mobility, UPL, Zydus Lifesciences, Abbott India, Amber Enterprises India, Amara Raja Energy &amp;amp; Mobility, Aster DM Healthcare, Cholamandalam Investment and Finance Company, Crompton Greaves Consumer Electricals, Cummins India, Godrej Properties, Hexaware Technologies, Mankind Pharma, Multi Commodity Exchange of India, Saatvik Green Energy, and Smartworks Coworking Spaces will announce their quarterly earnings on November 6.

Quarterly Earnings

Grasim Industries Q2 (Standalone YoY)

Profit jumps 11.6% to Rs 804.6 crore Vs Rs 720.9 crore

Revenue soars 26% to Rs 9,610.3 crore Vs Rs 7,623.3 crore

One 97 Communications Paytm Q2 (Consolidated YoY)

Profit falls sharply to Rs 21 crore Vs Rs 928 crore

Revenue grows 24.2% to Rs 2,061 crore Vs Rs 1,659 crore

Exceptional loss at Rs 190 crore Vs exceptional gain of Rs 1,345 crore

Paytm partners with Groq to power real-time AI for payments and platform intelligence

InterGlobe Aviation Q2 (Consolidated)

Loss widens to Rs 2,582.1 crore Vs loss of Rs 986.7 crore

Revenue grows 9.3% to Rs 18,555.3 crore Vs Rs 16,969.6 crore

EBITDAR plunges 54.2% to Rs 1,114.3 crore Vs Rs 2,434 crore

EBITDAR margin drops to 6% Vs 14.3%

EBITDAR (excluding forex) zooms 42.5% to Rs 3,800.3 crore Vs Rs 2,666.8 crore

EBITDAR margin (excluding forex) expands to 20.5% Vs 15.7%

Britannia Industries Q2 (Consolidated YoY)

Profit zooms 23.1% to Rs 654.5 crore Vs Rs 531.5 crore

Revenue grows 3.7% to Rs 4,840.6 crore Vs Rs 4,667.6 crore

Board appoints Rakshit Hargave as an Additional Whole-Time Director and Chief Executive Officer of Britannia

Indian Hotels Company Q2 (Consolidated YoY)

Profit sinks 48.6% to Rs 284.9 crore Vs Rs 554.6 crore

Revenue rises 11.8% to Rs 2,040.9 crore Vs Rs 1,826.1 crore

Delhivery Q2 (Consolidated YoY)

Loss stands at Rs 50.4 crore Vs profit of Rs 10.2 crore

Revenue increases 16.9% to Rs 2,559.3 crore Vs Rs 2,189.7 crore

Vivek Pabari to take over as Chief Financial Officer of the company

Redington Q2 (Consolidated YoY)

Profit jumps 23.8% to Rs 350.2 crore Vs Rs 282.9 crore

Revenue soars 16.8% to Rs 29,075.6 crore Vs Rs 24,895.6 crore.

Godrej Agrovet Q2 (Consolidated YoY)

Profit falls 12% to Rs 84.3 crore Vs Rs 95.8 crore

Revenue increases 4.8% to Rs 2,567.4 crore Vs Rs 2,448.8 crore

International Gemmological Institute India Q2 (Consolidated YoY)

Profit grows 18.4% to Rs 129.8 crore Vs Rs 109.6 crore

Revenue jumps 21.4% to Rs 303.7 crore Vs Rs 250.1 crore

CSB Bank Q2 (YoY)

Profit increases 15.8% to Rs 160.3 crore Vs Rs 138.4 crore

Net interest income soars 15.3% to Rs 423.6 crore Vs Rs 367.5 crore

Provisions &amp;amp; contingencies zoom 357.6% to Rs 63.7 crore Vs Rs 13.9 crore

Gross NPA falls to 1.81% Vs 1.84% (QoQ)

Net NPA declines to 0.52% Vs 0.66% (QoQ)

Kaynes Technology India Q2 (Consolidated YoY)

Profit spikes 101.7% to Rs 121.4 crore Vs Rs 60.2 crore

Revenue zooms 58.4% to Rs 906.2 crore Vs Rs 572.1 crore

Chalet Hotels Q2 (Consolidated YoY)

Profit stands at Rs 154.8 crore Vs loss of Rs 138.5 crore

Revenue surges 95% to Rs 735.3 crore Vs Rs 377 crore

Berger Paints India Q2 (Consolidated YoY)

Profit falls 23.5% to Rs 206.4 crore Vs Rs 270 crore

Revenue rises 1.9% to Rs 2,827.5 crore Vs Rs 2,774.6 crore

TeamLease Services Q2 (Consolidated YoY)

Profit grows 12% to Rs 27.5 crore Vs Rs 24.6 crore

Revenue increases 8.4% to Rs 3,032 crore Vs Rs 2,796.8 crore

Deepak Fertilisers &amp;amp; Petrochemicals Corporation Q2 (Consolidated YoY)

Profit rises 1.5% to Rs 213.2 crore Vs Rs 210.1 crore

Revenue soars 9.4% to Rs 3,005.8 crore Vs Rs 2,746.7 crore

Motherson Sumi Wiring India Q2 (Consolidated YoY)

Profit jumps 8.7% to Rs 165.3 crore Vs Rs 152 crore

Revenue surges 18.8% to Rs 2,761.9 crore Vs Rs 2,325.6 crore

Apollo Micro Systems Q2 (Consolidated YoY)

Profit zooms 98.1% to Rs 31.1 crore Vs Rs 15.7 crore

Revenue surges 40.2% to Rs 225.3 crore Vs Rs 160.7 crore

Metropolis Healthcare Q2 (Consolidated YoY)

Profit grows 13.2% to Rs 52.7 crore Vs Rs 46.5 crore

Revenue increases 22.7% to Rs 429.2 crore Vs Rs 349.8 crore

Aditya Birla Fashion and Retail Q2 (Standalone YoY)

Loss narrows to Rs 90.9 crore Vs loss of Rs 138.7 crore

Revenue soars 7.5% to Rs 1,491.8 crore Vs Rs 1,387.4 crore

Gujarat Pipavav Port Q2 (Consolidated YoY)

Profit zooms 112.9% to Rs 160.7 crore Vs Rs 75.5 crore

Revenue grows 31.8% to Rs 299.4 crore Vs Rs 227 crore

Garden Reach Shipbuilders &amp;amp; Engineers Q2 (Consolidated YoY)

Profit spikes 57.3% to Rs 153.8 crore Vs Rs 97.8 crore

Revenue surges 45.5% to Rs 1,677.4 crore Vs Rs 1,152.9 crore

Stocks to Watch

RBL Bank

Mahindra and Mahindra is likely to sell its entire 3.45% stake in the bank, with the block size likely at $78 million (Rs 682 crore) and a floor price of Rs 317 per share, reports CNBC-TV18 quoting sources.

Tata Consultancy Services

The IT services, consulting, and business solutions company has expanded its 18-year partnership with ABB to modernize ABB’s global hosting operations, simplify its IT landscape, and strengthen its digital foundation to drive resilience and innovation.

Adani Energy Solutions

The company has signed an agreement with RSWM for the supply of 60 MW of renewable energy to RSWM’s multiple plant locations. RSWM invested Rs 60 crore under the Group Captive Scheme with a renewable generation company (genco) for the supply of 31.53 crore units of green power per annum to its manufacturing facilities across Rajasthan. With this addition, the contribution of renewable energy in RSWM’s total energy requirement will rise from the current 33% to 70% in the near future (two-thirds of its total energy mix).

Zydus Lifesciences

The company has received an Establishment Inspection Report (EIR) from the USFDA (US Food and Drug Administration) for its manufacturing facility in SEZ II, Ahmedabad.

The USFDA conducted an inspection at the group’s manufacturing plant during August 11-14, 2025. The inspection was a Pre-Approval Inspection (PAI). The USFDA has concluded this inspection as closed, with no observations. The EIR has classified the facility as No Action Indicated (NAI).

Marksans Pharma

The company's wholly owned subsidiary, Relonchem in the UK, has received marketing authorization for its product Exemestane 25mg film-coated tablets from the UK MHRA. Exemestane tablets are used to treat hormone-positive breast cancer in postmenopausal women.

Force Motors

The company reported total sales of 2,835 units in the month of October, growing 32.1% compared to 2,146 units sold in the same month last year.

Gujarat Narmada Valley Fertilizers and Chemicals Company

The Board has approved the appointment of Manoj Kumar Das, IAS, as Director and Chairman of the company.

Bulk Deals

Stallion India Fluorochemicals

Promoter Shazad Sheriar Rustomji sold 8.08 lakh shares (equivalent to 1.01% of paid-up equity) in Stallion India at Rs 247.65 per share, valued at Rs 20.01 crore. The total promoters' shareholding in the company was 67.9 percent as of September 2025.

However, Savita Jayesh Shah acquired 4.04 lakh shares (0.5% stake), and Jayeshbhai Nagindas Shah bought 4.04 lakh shares (0.5% stake) in Stallion India at Rs 247.65 per share.

AAA Technologies

Promoter Anjay Ratanlal Agarwal sold 1 lakh shares in the information technology and cyber security auditing and consulting company at Rs 93.1 per share for a total of Rs 93.1 lakh to Nautilus.

Mainboard Listing

Orkla India

SME Listing

Safecure Services

Stocks Trade Ex-Dividend

Hindustan Petroleum Corporation
Nippon Life India Asset Management
Share India Securities
TD Power Systems
Vaibhav Global

Promoter Shazad Sheriar Rustomji has offloaded over a percent stake in Stallion India Fluorochemicals, which specialises in selling refrigerant and industrial gases, via open market transactions on November 4.

<a href="https://www.moneycontrol.com/india/stockpricequote/chemicals/stallionindiafluorochemicals/SIFL">Stallion India Fluorochemicals</a> shares were locked in 5 percent lower circuit for fourth consecutive session, closing at Rs 247.65 on the NSE. Overall, it has been under pressure since hitting record high on October 17, barring one-day rebound, losing in total over 41 percent in the same period.

Shazad Sheriar Rustomji sold 8.08 lakh shares (equivalent to 1.01 percent of paid-up equity) at Rs 247.65 per share, valued at Rs 20.01 crore. Total promoters' shareholding in the company was 67.9 percent as of September 2025.

However, Savita Jayesh Shah acquired 4.04 lakh shares (0.5 percent stake), and Jayeshbhai Nagindas Shah bought 4.04 lakh shares (0.5 percent stake) in Stallion India at Rs 247.65 per share.

<a href="https://www.moneycontrol.com/india/stockpricequote/software/aaatechnologies/ATL">AAA Technologies</a> also saw some action on Tuesday, falling 1.28 percent to Rs 94.4. Promoter Anjay Ratanlal Agarwal sold 1 lakh shares in the information technology and cyber security auditing and consulting company at Rs 93.1 per share for Rs 93.1 lakh, to Nautilus.

Meanwhile, Craft Emerging Market Fund PCC- Citadel Capital Fund bought 66,000 shares in <a href="https://www.moneycontrol.com/india/stockpricequote/retailing/foneboxretail/FR01">Fonebox Retail</a> at Rs 97.46 per share, from Aarth.AIF Growth Fund.

Promoter sells over 1% stake in Stallion India Fluorochemicals

Promoter Shazad Sheriar Rustomji has offloaded over a percent stake in Stallion India Fluorochemicals, which specialises in selling refrigerant and industrial gases, via open market transactions on November 4.

Stallion India Fluorochemicals shares were locked in 5 percent lower circuit for fourth consecutive session, closing at Rs 247.65 on the NSE. Overall, it has been under pressure since hitting record high on October 17, barring one-day rebound, losing in total over 41 percent in the same period.

Shazad Sheriar Rustomji sold 8.08 lakh shares (equivalent to 1.01 percent of paid-up equity) at Rs 247.65 per share, valued at Rs 20.01 crore. Total promoters' shareholding in the company was 67.9 percent as of September 2025.

However, Savita Jayesh Shah acquired 4.04 lakh shares (0.5 percent stake), and Jayeshbhai Nagindas Shah bought 4.04 lakh shares (0.5 percent stake) in Stallion India at Rs 247.65 per share.

AAA Technologies also saw some action on Tuesday, falling 1.28 percent to Rs 94.4. Promoter Anjay Ratanlal Agarwal sold 1 lakh shares in the information technology and cyber security auditing and consulting company at Rs 93.1 per share for Rs 93.1 lakh, to Nautilus.

Meanwhile, Craft Emerging Market Fund PCC- Citadel Capital Fund bought 66,000 shares in Fonebox Retail at Rs 97.46 per share, from Aarth.AIF Growth Fund.

Life Insurance Corporation of India (LIC), the country’s largest state-owned insurer, emerged as a powerful stabilising force for domestic equities in the September 2025 quarter, stepping in with aggressive buying during a period marked by sharp market swings and heavy foreign selling.

The insurance giant made net equity purchases of more than Rs 21,700 crore during the quarter. LIC raised its stake in 76 listed companies and trimmed exposure in 81, while also adding 13 new stocks to its portfolio for the first time. Its name, however, disappeared from the shareholding pattern of 31 companies, though it remains unclear whether the insurer fully exited these counters or if its stake simply fell below the one percent reporting threshold.

Despite the buying spree, the total market value of LIC’s listed equity portfolio slipped 1.7 percent to Rs 16.09 lakh crore at the end of September, from Rs 16.36 lakh crore in June, reflecting the broad market decline. At the close of the quarter, LIC held positions across 322 listed companies.

State Bank of India emerged as LIC’s marquee bet, with the insurer picking up 6.42 crore additional shares worth Rs 5,599 crore. It also boosted stakes in Sun Pharmaceuticals and HCL Technologies, acquiring shares worth Rs 3,226 crore and Rs 2,939 crore, respectively. Other notable increases included Pidilite Industries (Rs 2,234 crore), Coal India (Rs 2,119 crore), NTPC (Rs 1,992 crore), Tata Motors Passenger Vehicles (Rs 1,904 crore), Cipla (Rs 1,686 crore) and Tata Consultancy Services (Rs 1,654 crore).

<img class="alignnone size-full wp-image-13650757" src="https://images.moneycontrol.com/static-mcnews/2025/11/20251104022855_LIC-Portfolio-in-Q2.jpg" alt="LIC Portfolio in Q2" width="1944" height="4248" />

On the other side, HDFC Bank saw the steepest selling by LIC, with the insurer paring holdings worth Rs 3,130 crore. This was followed by stake cuts in ICICI Bank (Rs 2,338 crore) and Larsen &amp; Toubro (Rs 2,243 crore). LIC also reduced exposure to Bharti Airtel (Rs 2,205 crore), Mahindra &amp; Mahindra (Rs 2,149 crore), Maruti Suzuki (Rs 2,052 crore) and Kotak Mahindra Bank (Rs 1,994 crore).

Among newly added stocks, BSE Ltd topped the list, with LIC purchasing 2.28 crore shares valued at Rs 4,637 crore. The insurer also took significant positions in Yes Bank (Rs 2,653 crore) and ABB India (Rs 2,424 crore). Other fresh bets included Varun Beverages (Rs 1,982 crore), Shriram Finance (Rs 1,492 crore) and Persistent Systems (Rs 819 crore).

Meanwhile, several prominent companies saw LIC’s shareholding slip off their registers. These included NMDC, where LIC previously held 48.58 crore shares valued at Rs 3,402 crore as of June, along with Coforge and Eicher Motors, whose LIC-held stakes in the previous quarter were worth about Rs 3,398 crore and Rs 2,943 crore, respectively. Other exits or stake reductions involved Apollo Hospitals (Rs 2,258 crore), TVS Motor (Rs 1,583 crore), Piramal Enterprises (Rs 1,583 crore), HDFC AMC (Rs 1,162 crore) and Dixon Technologies (Rs 972 crore).

Despite the churn, LIC’s top holdings remain anchored in India’s largest corporates. Reliance Industries continues to be its single biggest holding at Rs 1.38 lakh crore, followed by ITC at Rs 82,343 crore and Larsen &amp; Toubro at Rs 67,878 crore. SBI (Rs 66,764 crore), Infosys (Rs 64,670 crore), TCS (Rs 60,916 crore) and IDBI Bank (Rs 54,757 crore) also feature among its largest equity positions.

The September quarter proved tough for Indian markets, with geopolitical tensions and foreign portfolio outflows weighing heavily on sentiment. The Sensex dropped four percent, while the Nifty slipped 3.6 percent. Broader indices fared worse, with the BSE MidCap and SmallCap gauges declining 4.5 percent and 4.2 percent, respectively.

LIC lifts stakes in SBI, Coal India, Sun Pharma, HCL; cuts exposure in HDFC Bank, ICICI Bank

Life Insurance Corporation of India (LIC), the country’s largest state-owned insurer, emerged as a powerful stabilising force for domestic equities in the September 2025 quarter, stepping in with aggressive buying during a period marked by sharp market swings and heavy foreign selling.

The insurance giant made net equity purchases of more than Rs 21,700 crore during the quarter. LIC raised its stake in 76 listed companies and trimmed exposure in 81, while also adding 13 new stocks to its portfolio for the first time. Its name, however, disappeared from the shareholding pattern of 31 companies, though it remains unclear whether the insurer fully exited these counters or if its stake simply fell below the one percent reporting threshold.

Despite the buying spree, the total market value of LIC’s listed equity portfolio slipped 1.7 percent to Rs 16.09 lakh crore at the end of September, from Rs 16.36 lakh crore in June, reflecting the broad market decline. At the close of the quarter, LIC held positions across 322 listed companies.

State Bank of India emerged as LIC’s marquee bet, with the insurer picking up 6.42 crore additional shares worth Rs 5,599 crore. It also boosted stakes in Sun Pharmaceuticals and HCL Technologies, acquiring shares worth Rs 3,226 crore and Rs 2,939 crore, respectively. Other notable increases included Pidilite Industries (Rs 2,234 crore), Coal India (Rs 2,119 crore), NTPC (Rs 1,992 crore), Tata Motors Passenger Vehicles (Rs 1,904 crore), Cipla (Rs 1,686 crore) and Tata Consultancy Services (Rs 1,654 crore).



On the other side, HDFC Bank saw the steepest selling by LIC, with the insurer paring holdings worth Rs 3,130 crore. This was followed by stake cuts in ICICI Bank (Rs 2,338 crore) and Larsen &amp;amp; Toubro (Rs 2,243 crore). LIC also reduced exposure to Bharti Airtel (Rs 2,205 crore), Mahindra &amp;amp; Mahindra (Rs 2,149 crore), Maruti Suzuki (Rs 2,052 crore) and Kotak Mahindra Bank (Rs 1,994 crore).

Among newly added stocks, BSE Ltd topped the list, with LIC purchasing 2.28 crore shares valued at Rs 4,637 crore. The insurer also took significant positions in Yes Bank (Rs 2,653 crore) and ABB India (Rs 2,424 crore). Other fresh bets included Varun Beverages (Rs 1,982 crore), Shriram Finance (Rs 1,492 crore) and Persistent Systems (Rs 819 crore).

Meanwhile, several prominent companies saw LIC’s shareholding slip off their registers. These included NMDC, where LIC previously held 48.58 crore shares valued at Rs 3,402 crore as of June, along with Coforge and Eicher Motors, whose LIC-held stakes in the previous quarter were worth about Rs 3,398 crore and Rs 2,943 crore, respectively. Other exits or stake reductions involved Apollo Hospitals (Rs 2,258 crore), TVS Motor (Rs 1,583 crore), Piramal Enterprises (Rs 1,583 crore), HDFC AMC (Rs 1,162 crore) and Dixon Technologies (Rs 972 crore).

Despite the churn, LIC’s top holdings remain anchored in India’s largest corporates. Reliance Industries continues to be its single biggest holding at Rs 1.38 lakh crore, followed by ITC at Rs 82,343 crore and Larsen &amp;amp; Toubro at Rs 67,878 crore. SBI (Rs 66,764 crore), Infosys (Rs 64,670 crore), TCS (Rs 60,916 crore) and IDBI Bank (Rs 54,757 crore) also feature among its largest equity positions.

The September quarter proved tough for Indian markets, with geopolitical tensions and foreign portfolio outflows weighing heavily on sentiment. The Sensex dropped four percent, while the Nifty slipped 3.6 percent. Broader indices fared worse, with the BSE MidCap and SmallCap gauges declining 4.5 percent and 4.2 percent, respectively.

Electric Equipment - Switchgears Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Electric Equipment - Switchgears industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Zydus Lifesciences gets EIR from USFDA for Ahmedabad facility; shares trade lower

Marksans Pharma shares rise on breast cancer drug approval from UK MHRA

Stocks to Watch Today: RBL Bank, TCS, Zydus Life, Britannia, Gujarat Pipavav, Garden Reach, Apollo Micro Systems, Chalet Hotels, CSB Bank, Orkla India, Paytm in focus on 06 November

Promoter sells over 1% stake in Stallion India Fluorochemicals

LIC lifts stakes in SBI, Coal India, Sun Pharma, HCL; cuts exposure in HDFC Bank, ICICI Bank

Electric Equipment - Switchgears Industry StocksCheck latest stock performance, list of stocks, earnings review & more details about the Electric Equipment - Switchgears industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Zydus Lifesciences gets EIR from USFDA for Ahmedabad facility; shares trade lower

Marksans Pharma shares rise on breast cancer drug approval from UK MHRA

Stocks to Watch Today: RBL Bank, TCS, Zydus Life, Britannia, Gujarat Pipavav, Garden Reach, Apollo Micro Systems, Chalet Hotels, CSB Bank, Orkla India, Paytm in focus on 06 November

Promoter sells over 1% stake in Stallion India Fluorochemicals

LIC lifts stakes in SBI, Coal India, Sun Pharma, HCL; cuts exposure in HDFC Bank, ICICI Bank

Electric Equipment - Switchgears Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Electric Equipment - Switchgears industry stocks.